Education
About Us
Working with TipRanks
Follow Us
Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $17.5→$20 | ― | 3.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $315→$295 | ― | 22.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $105→$108 | ― | 13.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $97 | ― | 13.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $10 | ― | 0.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $184 | ― | 0.90% | Reiterated | ||||
 | Astrana Health | BUY $46 | ― | -13.60% | Reiterated | Truist Financial Reaffirms Their Buy Rating on Astrana Health (ASTH) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $40 | ― | 4.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $45 | ― | 22.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $280 | ― | 24.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $32→$34 | ― | 8.80% | Reiterated | ||||
 | Constellation Brands | BUY $200 | ― | -0.30% | Reiterated | Constellation Brands: Buy Rating Justified by Anticipated Beer Sales Recovery and Strategic Cost Management | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $300→$327 | ― | 15.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $200→$212 | ― | 15.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $100→$115 | ― | 15.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $51→$57 | ― | 15.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $26→$27 | ― | 15.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $19→$20 | ― | 15.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $78→$85 | ― | 15.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $55→$59 | ― | 15.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $55→$59 | ― | 15.30% | Reiterated | ||||
 | Archer Aviation | BUY $18 | ― | -11.60% | Reiterated | Archer Aviation's Promising Growth and Market Readiness Justify Buy Rating | |||
 | VYNE Therapeutics | BUY $4.5 | ― | -19.30% | Reiterated | Optimistic Outlook for VYNE Therapeutics Amid Promising VYN202 Program Developments | |||
 | Belite Bio, Inc. ADR | BUY $100 | ― | -8.80% | Reiterated | Positive Buy Rating for Belite Bio Driven by Phase 3 PHOENIX Trial Milestone and Regulatory Designations | |||
| NovoCure | BUY $38 | ― | -7.10% | Reiterated | Promising Phase 3 Results for NovoCure's TTFields Therapy in Pancreatic Cancer | |||
| Melco Resorts & Entertainment | BUY $8→$9 | ― | -1.50% | Reiterated | Goldman Sachs Keeps Their Buy Rating on Melco Resorts & Entertainment (MLCO) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $23 | ― | 1.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $60 | ― | 15.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $210 | ― | 9.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $21 | ― | 33.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $39 | ― | 8.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $250 | ― | 12.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $36 | ― | 16.50% | Reiterated | ||||
 | Fluence Energy | HOLD $5 | ― | -4.20% | Reiterated | Fluence Energy (FLNC) Receives a Hold from Barclays | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $283 | ― | 19.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $210 | ― | 10.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $152 | ― | 11.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $24→$26 | ― | 14.70% | Reiterated | ||||
 | Visa | BUY $396 | ― | -1.30% | Reiterated | Barclays Keeps Their Buy Rating on Visa (V) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $240 | ― | 2.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $303 | ― | 1.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $273 | ― | 11.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $11 | ― | 14.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $21 | ― | 19.40% | Upgraded | ||||
DuPont de Nemours | BUY $75→$85 | ― | -0.60% | Reiterated | Citi adds 'upside 90-day catalyst watch' on DuPont | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $185 | ― | 19.40% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $20→$22 | ― | 23.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $172 | ― | 7.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $150 | ― | 4.00% | Reiterated | ||||
 | Kymera Therapeutics | BUY $79→$70 | ― | -6.10% | Initiated | Kymera Therapeutics: Buy Rating Backed by Innovative Drug Discovery and Strategic Partnerships |
Rows:
